首页> 外文OA文献 >Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN ® Basal–Bolus Type 1): 2‐year results of a randomized clinical trial

【2h】

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN ® Basal–Bolus Type 1): 2‐year results of a randomized clinical trial

机译：胰岛素Degludec在基底胰岛素Aspart在1型糖尿病（Begin®Basal-Zolus 1）中的胰岛素胰岛素中，胰岛素Degludec提高了夜间低血糖症的风险低于胰岛素胰岛素的血糖控制：2年的随机临床试验结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
B. W. Bode; J. B. Buse; M. Fisher; S. K. Garg; M. Marre; L. Merker; E. Renard; D. L. Russell‐Jones; C. T. Hansen; A. Rana; S. R. Heller;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN? Basal-Bolus Type 1): 2-year results of a randomized clinical trial [J] . BodeB.W., BuseJ.B., FisherM., Diabetic medicine: A journal of the British Diabetic Association . 2013,第11期

机译：在1型糖尿病（BEGIN？Basal-Bolus 1型）中，就餐时服用门冬胰岛素的基础大剂量治疗，胰岛素degludec可以比甘精胰岛素改善夜间血糖低的血糖控制风险：一项为期2年的随机临床试验结果
2. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): A phase 3, randomised, open-label, treat-to-target non-inferiority trial [J] . HellerS., BuseJ., FisherM., The Lancet . 2012,第9825期

机译：地格胰岛素，一种超长效基础胰岛素，与甘精胰岛素相比，在1型糖尿病（BEGIN基础-布鲁斯1型）中采用进餐胰岛素门冬胰岛素治疗：3期，随机，开放标签，靶向治疗非自卑感试验
3. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): A phase 3, randomised, open-label, treat-to-target non-inferiority trial [J] . GarberA.J., KingA.B., DelPratoS., The Lancet . 2012,第9825期

机译：degdegc胰岛素，一种超长效基础胰岛素，与甘精胰岛素相比，在2型糖尿病（BEGIN基础-布鲁斯2型）中采用进餐胰岛素门冬胰岛素治疗：3期，随机，开放标签，靶向治疗非自卑感试验
4. Switching to insulin glargine 300 U/mL from other basal insulin analogues provides less 24-hour glucose variability in hospitalized patients with type 1 diabetes [C] . V.V. Klimontov, E.A. Koroleva, O.N. Fazullina International Multiconference Bioinformatics of Genome Regulation and StructureSystems Biology . 2018

机译：从其他基础胰岛素类似物转换为甘精胰岛素300 U / mL可使住院的1型糖尿病患者的24小时葡萄糖变异性降低
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial [O] . B W Bode, J B Buse, M Fisher, -1

机译：简短报告：在1型糖尿病（BEGIN®Basal-Bolus 1型）中就餐时服用门冬胰岛素的基础-大剂量治疗胰岛素地格曲德改善血糖控制的夜间低血糖风险低于甘精胰岛素其2年随机临床试验结果
7. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1) [O] . I. B. Hirsch, E. Franek, H. Mersebach, 2016

机译：胰岛素Degludec /胰岛素Aspart用推注蛋白酶胰岛素Aspart的安全性和疗效与1型糖尿病患者的标准基础 - 推注治疗：随机临床试验的1年结果（Boost®T1）

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN ® Basal–Bolus Type 1): 2‐year results of a randomized clinical trial

著录项

相似文献

相关主题

期刊订阅